Cargando…
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
Bisphosphonates are the leading drugs for the treatment of osteoporosis. In randomized controlled trials (RCTs), alendronate, risedronate, and zoledronate have shown to reduce the risk of vertebral, nonvertebral, and hip fractures, whereas RCTs with ibandronate show antifracture efficacy at vertebra...
Autores principales: | Pazianas, Michael, Cooper, Cyrus, Ebetino, F Hal, Russell, R Graham G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909499/ https://www.ncbi.nlm.nih.gov/pubmed/20668715 |
Ejemplares similares
-
Atrial fibrillation and the use of oral bisphosphonates
por: Pazianas, Michael, et al.
Publicado: (2011) -
Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?
por: Bandeira, Francisco, et al.
Publicado: (2020) -
Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010) -
Eliminating the need for fasting with oral administration of bisphosphonates
por: Pazianas, Michael, et al.
Publicado: (2013) -
Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
por: Reginster, Jean-Yves, et al.
Publicado: (2006)